Copyright
©2014 Baishideng Publishing Group Inc. All rights reserved.
World J Clin Oncol. Dec 10, 2014; 5(5): 858-864
Published online Dec 10, 2014. doi: 10.5306/wjco.v5.i5.858
Published online Dec 10, 2014. doi: 10.5306/wjco.v5.i5.858
Erlotinib usage after prior treatment with gefitinib in advanced non-small cell lung cancer: A clinical perspective and review of published literature
Navneet Singh, Aditya Jindal, Digambar Behera, Department of Pulmonary Medicine, Postgraduate Institute of Medical Education and Research, Chandigarh 160012, India
Author contributions: All the authors equally contributed to this work.
Correspondence to: Navneet Singh, MD, DM, FACP, FCCP, FICS, Assistant Professor, Department of Pulmonary Medicine, Postgraduate Institute of Medical Education and Research, Sector 12, Chandigarh 160012, India. singh.navneet@pgimer.edu.in
Telephone: +91-172-2756826 Fax: +91-172-2745959
Received: May 3, 2014
Revised: July 19, 2014
Accepted: October 1, 2014
Published online: December 10, 2014
Revised: July 19, 2014
Accepted: October 1, 2014
Published online: December 10, 2014
Core Tip
Core tip: This manuscript is focused on the controversial yet interesting topic of whether erlotinib provides clinical benefit amongst patients who have experienced disease progression after prior therapy with gefitinib-both drugs being tyrosine kinase inhibitors of the epidermal growth factor receptor. We have reviewed available literature on this topic, carried out a pooled analysis on available data and hope readers find it useful in clearing the confusion related to this topic.